Novartis retreat from NASH takes down $80 M alliance with Pliant Therapeutics ..
Hopefully CYDY will conduct little bigger study for NASH soon , since small sample they did showed at 14 weeks better results in fibrosis then 54 weeks treatment by Madrigal drug...
What Dr Arman said is they are planning two different studies in NASH , probably starting in 2023 , one in a general population , and one in HIV patients . Since HIV positive patients showing severe generalized inflammation , and about 60% developing fatty liver , and from these some going in to NASH.
Market Data 
Markets 
AI
